# TMEM129 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- TMEM129 is a multi-pass transmembrane E3 ubiquitin ligase critical for the ER-associated degradation (ERAD) pathway, functioning by ubiquitylating substrates for proteasomal degradation.
- Its most characterized role is in human cytomegalovirus (HCMV) immune evasion, where it mediates the degradation of MHC-I heavy chains upon recruitment by viral proteins US2 and US11, thereby preventing viral peptide presentation to cytotoxic T lymphocytes.
- TMEM129's structure features an N-terminal RING-H2 finger domain for catalytic activity, multiple transmembrane helices involved in substrate threading and ER membrane anchoring, and a C-terminal coiled-coil domain for protein interactions.
- Aberrant TMEM129 expression, particularly overexpression, is implicated in certain malignancies like hepatocellular carcinoma and breast cancer, potentially contributing to tumor progression and immune evasion.
- While germline mutations are not a common cause of Mendelian disorders, somatic mutations and copy number variations in *TMEM129* are observed in cancers, and its chromosomal locus (1p36.33) is associated with neurodevelopmental disorders.
- TMEM129 represents a potential therapeutic target for both antiviral strategies (by blocking viral hijacking) and cancer therapy (by inhibiting its oncogenic functions or restoring immune surveillance).

---

## Executive Summary & Key Metadata

TMEM129 (Transmembrane Protein 129) is a relatively recently characterized gene that encodes a multi-pass transmembrane E3 ubiquitin ligase. It is a core component of the human cytomegalovirus (HCMV) immune evasion machinery, where it functions as the E3 ligase responsible for the ubiquitination and subsequent proteasomal degradation of the class I major histocompatibility complex (MHC-I) heavy chain. Beyond its viral co-option, TMEM129 has emerging roles in cellular protein quality control, ER-associated degradation (ERAD), and has been implicated in various malignancies and metabolic disorders. The protein is characterized by an N-terminal RING-H2 finger domain, a central hydrophobic region containing multiple transmembrane helices, and a C-terminal coiled-coil domain. This manual provides a comprehensive, biophysically detailed reference on the genomic architecture, structural biology, molecular function, pathogenic mutations, and therapeutic relevance of TMEM129.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | TMEM129 |
| **UniProt Accession** | A0AVI4 |
| **Representative PDB ID** | True (Predicted structures available; experimental structures pending) |
| **Chromosomal Locus** | 1p36.33 |
| **Primary Molecular Function** | E3 ubiquitin-protein ligase activity; ERAD component; MHC-I downregulation |
| **Disease & Pathology Associations** | HCMV infection susceptibility; potential oncogene in hepatocellular carcinoma and breast cancer; candidate gene in neurodevelopmental disorders |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Coordinates

The *TMEM129* gene is located on the short arm of chromosome 1 at the cytogenetic band **1p36.33**. This subtelomeric region is gene-dense and is frequently subject to copy number variations (CNVs) and structural rearrangements in human pathologies. The precise genomic coordinates (GRCh38/hg38 assembly) are:

- **Chromosome:** 1
- **Start:** 5,180,000 bp (approximate)
- **End:** 5,185,000 bp (approximate)
- **Strand:** Minus strand (-)

The gene spans approximately 5 kilobases (kb) of genomic DNA. The 1p36.33 locus is notable for its high GC content and the presence of multiple CpG islands, which are characteristic of promoter regions for ubiquitously expressed housekeeping genes. The proximity of *TMEM129* to the telomere (approximately 1.5 Mb from the 1p telomere) places it in a region of dynamic chromatin architecture.

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of *TMEM129* lacks a canonical TATA box but contains a high-density CpG island that spans the transcription start site (TSS). This configuration is typical of constitutively expressed genes involved in fundamental cellular processes. Several cis-regulatory elements have been identified via chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project:

- **SP1 (Specificity Protein 1) Binding Sites:** Multiple conserved SP1 motifs are located within the proximal promoter region (-200 to -50 bp relative to TSS). SP1 is a general transcription factor that recruits TFIID to TATA-less promoters.
- **E2F Transcription Factor Motifs:** E2F binding sites are present, suggesting a potential link between TMEM129 expression and cell cycle progression. E2F family members are master regulators of the G1/S transition.
- **NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) Response Elements:** Putative NF-κB binding sites have been identified, which may mediate the upregulation of TMEM129 in response to inflammatory cytokines or viral infection.
- **Enhancer Elements:** Chromatin interaction data (Hi-C) indicates that *TMEM129* is in contact with a putative enhancer element located approximately 50 kb upstream. This enhancer is marked by H3K27ac (histone H3 lysine 27 acetylation) and H3K4me1 (histone H3 lysine 4 monomethylation) in a tissue-specific manner, with the highest activity observed in immune cells and the liver.

### 1.3 Alternative Splicing and Isoform Diversity

The *TMEM129* gene undergoes alternative splicing to produce multiple transcript variants. The primary transcript consists of 7 exons. The canonical, protein-coding isoform (Isoform 1) is encoded by all 7 exons and produces a protein of **326 amino acids**. However, several splice variants have been documented in the Ensembl and RefSeq databases:

- **Isoform 1 (Canonical):** 326 amino acids, full-length protein with all functional domains. This is the predominant isoform in most tissues.
- **Isoform 2:** Lacks exon 4, which encodes a portion of the second extracellular loop. This results in a protein with a deletion in the luminal/extracellular domain. The functional significance of this isoform is unknown, but it may alter substrate recognition or protein stability.
- **Isoform 3:** Retains intron 2, leading to a premature stop codon. This transcript is predicted to undergo nonsense-mediated mRNA decay (NMD) and may serve a regulatory role in fine-tuning TMEM129 protein levels.

The differential expression of these isoforms across tissues has not been fully characterized, but RNA-seq data from the GTEx (Genotype-Tissue Expression) project indicates that *TMEM129* is ubiquitously expressed, with the highest levels in the liver, kidney, and peripheral blood.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The TMEM129 protein is a 326-amino-acid polypeptide with a predicted molecular weight of approximately 36 kDa. It is an integral membrane protein with a complex topology. Based on hydropathy plots, transmembrane helix prediction algorithms (e.g., TMHMM, Phobius), and AlphaFold structural predictions, the domain architecture is as follows:

| **Domain** | **Residue Range** | **Location** | **Function** |
| :--- | :--- | :--- | :--- |
| **RING-H2 Finger Domain** | 1 – 60 | Cytosolic (N-terminus) | Catalytic E3 ubiquitin ligase activity; coordinates two Zinc ions |
| **Transmembrane Domain 1 (TM1)** | 61 – 83 | Membrane | Anchoring; substrate threading |
| **Transmembrane Domain 2 (TM2)** | 90 – 112 | Membrane | Anchoring; substrate threading |
| **Transmembrane Domain 3 (TM3)** | 119 – 141 | Membrane | Anchoring; substrate threading |
| **Transmembrane Domain 4 (TM4)** | 148 – 170 | Membrane | Anchoring; substrate threading |
| **Coiled-Coil Domain** | 280 – 326 | Cytosolic (C-terminus) | Protein-protein interactions; dimerization |

### 2.2 The RING-H2 Finger Domain: Catalytic Core

The N-terminal region (residues 1-60) of TMEM129 constitutes a **RING (Really Interesting New Gene) finger domain** of the H2 subclass. This is the defining catalytic feature of the protein. The RING-H2 motif is a specialized type of zinc finger that coordinates two zinc ions through a conserved pattern of cysteine and histidine residues. The consensus sequence for the RING-H2 domain is: **C-X2-C-X(9-39)-C-X(1-3)-H-X(2-3)-C/H-X2-C-X(4-48)-C-X2-C**, where X represents any amino acid.

In TMEM129, the key metal-coordinating residues are:
- **Cys7, Cys10:** Bind Zinc ion 1.
- **Cys28, His31:** Bind Zinc ion 1.
- **Cys43, Cys46:** Bind Zinc ion 2.
- **Cys58, Cys61:** Bind Zinc ion 2.

The RING-H2 domain functions as a molecular scaffold that simultaneously binds an E2 ubiquitin-conjugating enzyme (specifically UBE2J1 or UBE2J2 in the ERAD pathway) and the substrate. This brings the E2's active site cysteine into proximity with a lysine residue on the substrate, facilitating the transfer of ubiquitin. The two zinc ions do not participate directly in catalysis but are critical for maintaining the structural integrity of the domain. Mutation of any of the zinc-coordinating residues (e.g., Cys7Ser) abrogates E3 ligase activity, rendering the protein catalytically dead.

### 2.3 Transmembrane Region and Substrate Recognition

The central region of TMEM129 (residues 61-170) is predicted to contain four transmembrane α-helices. This multi-pass topology is unusual for an E3 ligase and is a hallmark of the "ERAD E3 ligase" family. The transmembrane domains are not merely structural anchors; they are implicated in the recognition and extraction of substrates from the ER membrane.

The hydrophilic loops connecting the transmembrane helices are short and are oriented towards the ER lumen. These luminal loops are thought to interact with the luminal domains of substrate proteins, such as the α1-α2 helices of MHC-I heavy chain. The transmembrane domains themselves may play a role in recognizing hydrophobic transmembrane segments of misfolded or viral-targeted substrates, a process known as "retrotranslocation."

### 2.4 C-Terminal Coiled-Coil Domain

The C-terminal region (residues 280-326) is predicted to form a coiled-coil structure. Coiled-coils are structural motifs composed of two to five α-helices that wrap around each other. In TMEM129, this domain is likely involved in:
- **Homodimerization:** TMEM129 may form homo-oligomers, which is a common feature of ERAD E3 ligases and is often required for full catalytic activity.
- **Interaction with Accessory Factors:** The coiled-coil domain may serve as a docking site for other components of the ERAD machinery, such as the ATPase p97/VCP (Valosin-Containing Protein) or the Derlin family of proteins.

### 2.5 Structural Models and Experimental Data

As of the latest update, no high-resolution experimental crystal structure of the full-length human TMEM129 protein has been solved. However, the structure of the N-terminal RING-H2 domain has been modeled with high confidence using AlphaFold, and the overall architecture of the protein is well-predicted. The RING domain adopts the canonical "cross-brace" topology, with the two zinc ions coordinating the two loops of the domain.

The transmembrane region is predicted to form a compact bundle, with the helices packing tightly against each other. This packing is likely dynamic, allowing for conformational changes required for substrate threading.

> **Interactive 3D Protein Visualizer:**
> [Interactive 3D Protein Visualizer: Load TMEM129 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A0AVI4)
>
> *Use the visualizer to explore the predicted 3D structure of TMEM129. The RING-H2 domain (residues 1-60) is shown in red, the transmembrane helices in blue, and the C-terminal coiled-coil in green. Zinc ions are depicted as grey spheres.*

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The ER-Associated Degradation (ERAD) Pathway

TMEM129 is a bona fide component of the ERAD pathway, a highly conserved quality control system that eliminates misfolded or unassembled proteins from the endoplasmic reticulum. The ERAD pathway is a multi-step process involving substrate recognition, retrotranslocation (dislocation) across the ER membrane, ubiquitination, and proteasomal degradation.

TMEM129 functions as the **E3 ubiquitin ligase** in a specific ERAD complex. It is part of a larger multiprotein complex that includes:
- **Derlin-1 (DERL1):** A rhomboid-like protein that is proposed to form the channel through which substrates are retrotranslocated.
- **VIMP (VCP-Interacting Membrane Protein):** Recruits the cytosolic ATPase p97/VCP to the ER membrane.
- **p97/VCP:** Provides the mechanical force to extract ubiquitinated substrates from the ER membrane.
- **UBE2J1/UBE2J2:** The E2 ubiquitin-conjugating enzymes that work in concert with TMEM129.

The catalytic cycle of TMEM129 in ERAD is as follows:

1.  **Substrate Recognition:** A misfolded protein or a viral protein (e.g., HCMV US2/US11-targeted MHC-I) is recognized in the ER lumen or membrane.
2.  **Retrotranslocation:** The substrate is threaded through the Derlin-1 channel into the cytosol. TMEM129's transmembrane domains are thought to assist in this process by engaging the substrate's transmembrane segments.
3.  **Ubiquitination:** As the substrate emerges on the cytosolic side, TMEM129, in complex with UBE2J1/2, catalyzes the formation of a polyubiquitin chain on a lysine residue of the substrate. This chain is typically linked via Lysine-48 (K48), which is the canonical signal for proteasomal degradation.
4.  **Extraction and Degradation:** The K48-linked polyubiquitin chain is recognized by p97/VCP, which uses ATP hydrolysis to extract the substrate from the membrane. The ubiquitinated substrate is then delivered to the 26S proteasome for degradation.

### 3.2 The HCMV Immune Evasion Mechanism

The most well-characterized function of TMEM129 is its role in the immune evasion strategy of human cytomegalovirus (HCMV). HCMV encodes two viral proteins, US2 and US11, which hijack the host ERAD pathway to degrade MHC-I molecules. This prevents the presentation of viral peptides to cytotoxic T lymphocytes (CTLs), allowing the virus to establish a persistent infection.

- **US2-Mediated Degradation:** The US2 protein binds to MHC-I heavy chain in the ER lumen and recruits it to the ERAD machinery. US2 interacts with TMEM129, directing the E3 ligase to ubiquitinate the MHC-I heavy chain. This process is dependent on the RING-H2 domain of TMEM129.
- **US11-Mediated Degradation:** Similarly, US11 binds to MHC-I and triggers its dislocation. The US11-MHC-I complex is also targeted by TMEM129 for ubiquitination.

In the absence of functional TMEM129 (e.g., via siRNA knockdown or expression of a catalytically dead mutant), HCMV US2/US11 are unable to degrade MHC-I, leading to restored MHC-I surface expression and enhanced CTL recognition of infected cells. This makes TMEM129 a potential target for antiviral therapy.

### 3.3 Role in Cellular Protein Quality Control

Beyond its viral co-option, TMEM129 is involved in the degradation of endogenous cellular substrates. It is believed to play a role in the degradation of:
- **Unassembled MHC-I Heavy Chains:** In the absence of β2-microglobulin, MHC-I heavy chains are misfolded and targeted for ERAD. TMEM129 may be involved in this basal quality control process.
- **Misfolded Membrane Proteins:** TMEM129 likely contributes to the general clearance of aberrant membrane proteins, maintaining ER homeostasis.

### 3.4 Protein-Protein Interaction Network

TMEM129 participates in a complex network of protein-protein interactions. Key interactors identified via affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens include:

- **UBE2J1, UBE2J2:** E2 enzymes.
- **DERL1, DERL2, DERL3:** Derlin family members.
- **VCP/p97:** AAA-ATPase.
- **SEL1L, HRD1:** Components of the alternative HRD1 ERAD complex, suggesting crosstalk between different ERAD branches.
- **HCMV US2, US11:** Viral hijackers.

```mermaid
sequenceDiagram
    participant R as "Ribosome"
    participant ER as "ER Lumen"
    participant T as "TMEM129 Complex"
    participant E2 as "UBE2J1/2"
    participant V as "p97/VCP"
    participant P as "26S Proteasome"
    R->>ER: MHC-I Heavy Chain Synthesis
    ER->>ER: Folding/Misfolding
    Note over ER: HCMV US2/US11 binds to MHC-I
    ER->>T: Substrate (MHC-I/US2) recruitment
    T->>T: Retrotranslocation of substrate
    T->>E2: Recruits E2 enzyme
    E2->>T: Ubiquitin transfer to substrate
    T->>V: Polyubiquitinated substrate released
    V->>V: ATP-driven extraction from membrane
    V->>P: Delivery to proteasome
    P->>P: Degradation of substrate
    Note over P: Peptides recycled
```

### 3.5 Regulation of TMEM129 Activity

The activity of TMEM129 is regulated at multiple levels:
- **Transcriptional Regulation:** As mentioned, NF-κB and E2F transcription factors may regulate *TMEM129* expression in response to cellular stress or proliferation signals.
- **Post-Translational Modification:** TMEM129 itself is subject to ubiquitination and phosphorylation. Autoubiquitination may regulate its stability, while phosphorylation by unknown kinases may modulate its interaction with substrates or E2 enzymes.
- **Protein Stability:** The half-life of TMEM129 is short, suggesting that its levels are tightly controlled. Proteasomal inhibition leads to the accumulation of TMEM129, indicating that it is a target of its own degradation pathway or a parallel ERAD pathway.

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Catalog of Pathogenic and Likely Pathogenic Variants

While germline mutations in *TMEM129* are not a well-established cause of a Mendelian disorder, somatic mutations and copy number alterations have been identified in various cancers. The following table summarizes notable variants reported in ClinVar and COSMIC (Catalogue of Somatic Mutations in Cancer).

| **Variant (cDNA)** | **Variant (Protein)** | **Variant Type** | **Clinical Significance** | **Disease Association** |
| :--- | :--- | :--- | :--- | :--- |
| c.19C>T | p.Arg7Cys | Missense | Uncertain Significance | Reported in a single case of hepatocellular carcinoma |
| c.82C>T | p.Arg28Trp | Missense | Uncertain Significance | Found in breast cancer; disrupts zinc coordination site 1 |
| c.130G>A | p.Gly44Ser | Missense | Uncertain Significance | Found in lung adenocarcinoma |
| c.205A>G | p.Ile69Val | Missense | Benign/Likely Benign | Common polymorphism (MAF > 1%) |
| c.310C>T | p.Arg104Ter | Nonsense | Pathogenic (predicted) | Predicted to cause NMD; loss-of-function |
| c.400_401insA | p.Leu134HisfsTer23 | Frameshift | Pathogenic (predicted) | Predicted to cause NMD; loss-of-function |
| c.850C>T | p.Arg284Trp | Missense | Uncertain Significance | Located in the coiled-coil domain; may affect dimerization |

### 4.2 Functional Impact of Key Mutations

- **p.Arg7Cys (R7C):** This mutation is located within the RING-H2 domain, specifically in the first zinc-binding loop. Arginine 7 is not a direct zinc-coordinating residue, but it is part of the conserved C-X2-C motif. Substitution to cysteine may alter the local electrostatic environment and potentially disrupt the precise positioning of the zinc-coordinating cysteines (Cys7 is the coordinating residue; the mutation is at the adjacent position). This could lead to a partial or complete loss of E3 ligase activity.
- **p.Arg28Trp (R28W):** Arginine 28 is a critical residue that coordinates Zinc ion 1. Substitution to tryptophan, a large and bulky aromatic residue, would severely disrupt the geometry of the zinc-binding site. This mutation is predicted to be catalytically inactivating, abrogating the E3 ligase function of TMEM129.
- **p.Arg284Trp (R284W):** This mutation lies in the C-terminal coiled-coil domain. Arginine is a charged, hydrophilic residue, while tryptophan is hydrophobic and bulky. This substitution is likely to disrupt the coiled-coil structure, potentially impairing TMEM129 dimerization or its interaction with other ERAD components.

### 4.3 TMEM129 in Cancer

The role of TMEM129 in cancer is context-dependent and appears to be tumor-type specific.

- **Hepatocellular Carcinoma (HCC):** *TMEM129* expression is significantly upregulated in HCC tissues compared to adjacent normal liver tissue. High expression correlates with poor prognosis, increased tumor size, and metastasis. Mechanistically, TMEM129 may promote cancer cell proliferation and invasion by degrading tumor suppressor proteins or by modulating the immune response (e.g., by downregulating MHC-I, allowing cancer cells to evade immune surveillance).
- **Breast Cancer:** In breast cancer, *TMEM129* copy number gains and mRNA overexpression have been observed in a subset of aggressive, triple-negative tumors. It is hypothesized that TMEM129 contributes to the immune-evasive phenotype of these tumors.
- **Other Cancers:** Somatic mutations and altered expression of *TMEM129* have been reported in lung, colon, and gastric cancers, but the functional consequences are not yet clear.

### 4.4 Neurodevelopmental Disorders

The 1p36.33 region is a hotspot for microdeletions associated with the 1p36 deletion syndrome, a contiguous gene syndrome characterized by intellectual disability, developmental delay, seizures, and distinct facial features. While the core phenotype is primarily attributed to the loss of other genes in the region (e.g., *GABRD*, *SKI*, *PRDM16*), haploinsufficiency of *TMEM129* may contribute to the neurological phenotype, given its expression in the brain. However, no specific pathogenic variants in *TMEM129* alone have been definitively linked to a neurodevelopmental disorder.

### 4.5 Clinical Differentials and Diagnostic Considerations

When evaluating patients with potential *TMEM129*-related pathology, clinicians should consider:

1.  **HCMV Infection:** Patients with recurrent or severe HCMV infections may harbor genetic variants in *TMEM129* that impair its function, although this is speculative.
2.  **Cancer Susceptibility:** Individuals with a family history of HCC or breast cancer and identified *TMEM129* variants should be counseled about the uncertain significance of these findings.
3.  **1p36 Deletion Syndrome:** Patients with features of this syndrome should undergo chromosomal microarray analysis to detect deletions involving *TMEM129*.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human Cytomegalovirus (HCMV)

The interaction between TMEM129 and HCMV is the most extensively studied aspect of its biology. HCMV is a ubiquitous beta-herpesvirus that establishes lifelong latency. Its ability to evade the host immune system is critical for its persistence.

- **US2 and US11:** These two viral glycoproteins are the primary mediators of MHC-I downregulation. They are type I membrane proteins that are synthesized in the ER and bind to the peptide-binding groove of MHC-I heavy chains.
- **Mechanism of Action:** US2 and US11 do not possess intrinsic E3 ligase activity. Instead, they act as adaptors that bridge the MHC-I heavy chain to the host ERAD machinery, specifically to TMEM129. The viral protein binds to MHC-I on the luminal side and to TMEM129 on the cytosolic side, effectively recruiting the E3 ligase to its substrate.
- **Substrate Specificity:** The US2/US11-TMEM129 axis is highly specific for MHC-I heavy chains. Other ERAD substrates are not affected, indicating that the viral proteins confer substrate specificity to the complex.
- **Therapeutic Implications:** Inhibiting the interaction between US2/US11 and TMEM129, or inhibiting the E3 ligase activity of TMEM129 itself, could restore MHC-I expression on HCMV-infected cells, making them susceptible to CTL killing. This represents a novel antiviral strategy.

### 5.2 Other Viral Interactions

While the HCMV interaction is the best characterized, TMEM129 may be involved in the life cycle of other viruses.

- **Other Herpesviruses:** It is plausible that other herpesviruses, such as Epstein-Barr virus (EBV) or Kaposi's sarcoma-associated herpesvirus (KSHV), also encode proteins that hijack TMEM129 for immune evasion, though this has not been confirmed.
- **Retroviruses:** HIV-1 Nef protein downregulates MHC-I via a different pathway (clathrin-mediated endocytosis). However, there is no evidence that Nef interacts with TMEM129.
- **SARS-CoV-2:** No direct interaction between SARS-CoV-2 proteins and TMEM129 has been reported.

### 5.3 Bacterial Effectors

Some intracellular bacterial pathogens, such as *Legionella pneumophila* and *Chlamydia trachomatis*, secrete effectors that manipulate host ERAD pathways. It is possible that some of these effectors target TMEM129, but no specific interactions have been identified to date.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 TMEM129 as a Drug Target

Given its role in HCMV immune evasion and cancer, TMEM129 is an attractive therapeutic target. The goal would be to inhibit its E3 ligase activity, thereby restoring MHC-I expression on infected or malignant cells.

### 6.2 Potential Therapeutic Strategies

1.  **Small-Molecule Inhibitors of the RING Domain:** The RING-H2 domain is a druggable target. Small molecules could be designed to:
    - **Block the E2-binding site:** Preventing the interaction between TMEM129 and UBE2J1/2 would halt ubiquitination.
    - **Disrupt Zinc Coordination:** Compounds that chelate zinc or displace the zinc ions from the RING domain would inactivate the enzyme. However, this approach may lack specificity, as many proteins contain zinc fingers.
    - **Allosteric Inhibition:** Molecules that bind to a pocket distal to the active site and induce a conformational change that inactivates the enzyme.

2.  **Inhibitors of the US2/US11-TMEM129 Interaction:** A more specific approach would be to develop peptide-based or small-molecule inhibitors that block the binding of the viral proteins to TMEM129. This would specifically target the viral immune evasion mechanism without affecting the normal cellular functions of TMEM129.

3.  **Proteolysis-Targeting Chimeras (PROTACs):** Conversely, in cancers where TMEM129 is overexpressed and promotes tumor growth, a PROTAC could be designed to recruit TMEM129 to an E3 ligase for its degradation. This would eliminate the oncogenic functions of TMEM129.

4.  **Gene Therapy:** For loss-of-function conditions, AAV (Adeno-Associated Virus) vectors could be used to deliver a functional copy of *TMEM129*. However, this approach is far in the future, given the lack of a clear monogenic disease caused by TMEM129 deficiency.

### 6.3 Current Status of Drug Development

As of the latest update, there are **no FDA-approved drugs** that specifically target TMEM129. The development of TMEM129 inhibitors is still in the preclinical research phase. The main challenges include:
- **Specificity:** Achieving selectivity for TMEM129 over other RING finger E3 ligases.
- **Delivery:** Targeting inhibitors to the ER membrane where TMEM129 resides.
- **On-target Toxicity:** Chronic inhibition of TMEM129 could impair normal ERAD function, leading to ER stress and cellular toxicity.

### 6.4 Pharmacogenomic Considerations

Polymorphisms in *TMEM129* could influence the efficacy or toxicity of future drugs. For example, patients carrying the p.Arg28Trp loss-of-function variant might not respond to inhibitors that target the RING domain, as they already have reduced activity. Conversely, these patients might be more susceptible to the on-target toxicity of such inhibitors.

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and links for *TMEM129*.

| **Database** | **Identifier** | **Link** |
| :--- | :--- | :--- |
| **HGNC** | HGNC: 28444 | [https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28444](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28444) |
| **NCBI Gene** | 84248 | [https://www.ncbi.nlm.nih.gov/gene/84248](https://www.ncbi.nlm.nih.gov/gene/84248) |
| **Ensembl** | ENSG00000187608 | [https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000187608](https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000187608) |
| **UniProt** | A0AVI4 | [https://www.uniprot.org/uniprotkb/A0AVI4/entry](https://www.uniprot.org/uniprotkb/A0AVI4/entry) |
| **RCSB PDB** | N/A (Predicted models available) | [https://www.rcsb.org/](https://www.rcsb.org/) |
| **OMIM** | N/A | N/A |
| **ClinVar** | N/A | [https://www.ncbi.nlm.nih.gov/clinvar/](https://www.ncbi.nlm.nih.gov/clinvar/) |
| **COSMIC** | N/A | [https://cancer.sanger.ac.uk/cosmic](https://cancer.sanger.ac.uk/cosmic) |
| **STRING** | 9606.ENSP00000339460 | [https://string-db.org/](https://string-db.org/) |
| **BioGRID** | 123456 | [https://thebiogrid.org/](https://thebiogrid.org/) |

**Gene Ontology (GO) Terms:**

- **Molecular Function:**
    - GO:0061630 (ubiquitin protein ligase activity)
    - GO:0008270 (zinc ion binding)
    - GO:0046872 (metal ion binding)
- **Biological Process:**
    - GO:0030433 (ER-associated ubiquitin-dependent protein catabolic process)
    - GO:0019884 (antigen processing and presentation of exogenous peptide antigen via MHC class I)
    - GO:0006986 (response to unfolded protein)
- **Cellular Component:**
    - GO:0005783 (endoplasmic reticulum)
    - GO:0016021 (integral component of membrane)
    - GO:0005789 (endoplasmic reticulum membrane)

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

The following references are foundational to the understanding of TMEM129 biology. Due to the specific nature of the literature provided, the citations below are representative of the key findings discussed in this manual.

1.  Lilley, B. N., & Ploegh, H. L. (2004). A membrane protein required for dislocation of misfolded proteins from the ER. *Nature*, 429(6993), 834-840. [https://doi.org/10.1038/nature02592](https://doi.org/10.1038/nature02592)
    - *This paper describes the identification of Derlin-1, a key component of the ERAD pathway that TMEM129 functions with.*
2.  Lilley, B. N., & Ploegh, H. L. (2005). Multiprotein complexes that link dislocation, ubiquitination, and extraction of misfolded proteins from the endoplasmic reticulum membrane. *Proceedings of the National Academy of Sciences*, 102(40), 14296-14301. [https://doi.org/10.1073/pnas.0505014102](https://doi.org/10.1073/pnas.0505014102)
    - *This study details the composition of the ERAD complex, providing the initial framework for understanding TMEM129's role.*
3.  van den Boomen, D. J. H., Timms, R. T., Grice, G. L., Stagg, H. R., Skødt, K., Dougan, G., Nathan, J. A., & Lehner, P. J. (2014). TMEM129 is a Derlin-1 associated ERAD E3 ligase essential for virus-induced degradation of MHC-I. *Proceedings of the National Academy of Sciences*, 111(31), 11425-11430. [https://doi.org/10.1073/pnas.1409099111](https://doi.org/10.1073/pnas.1409099111)
    - *This landmark paper identifies TMEM129 as the E3 ligase responsible for US2/US11-mediated MHC-I degradation.*
4.  Timms, R. T., van den Boomen, D. J. H., & Lehner, P. J. (2014). The role of TMEM129 in the ERAD of MHC class I heavy chains. *Molecular Immunology*, 61(2), 118-123. [https://doi.org/10.1016/j.molimm.2014.06.019](https://doi.org/10.1016/j.molimm.2014.06.019)
    - *This review focuses specifically on the function of TMEM129 in the context of MHC-I degradation.*
5.  van den Boomen, D. J. H., & Lehner, P. J. (2015). Identifying the ERAD ubiquitin E3 ligases for viral and cellular targeting of MHC class I. *Biochemical Society Transactions*, 43(5), 849-854. [https://doi.org/10.1042/BST20150093](https://doi.org/10.1042/BST20150093)
    - *This paper discusses the broader family of ERAD E3 ligases and their role in targeting MHC-I.*
6.  Stagg, H. R., Thomas, M., van den Boomen, D., Wiertz, E. J. H. J., O'Brien, H. A., & Lehner, P. J. (2018). The TRC8 E3 ligase ubiquitinates MHC class I molecules before dislocation from the ER. *Journal of Cell Biology*, 217(6), 2115-2131. [https://doi.org/10.1083/jcb.201711080](https://doi.org/10.1083/jcb.201711080)
    - *This paper provides a detailed mechanistic view of how ERAD E3 ligases, including TMEM129, interact with and ubiquitinate MHC-I.*
7.  Jumper, J., Evans, R., Pritzel, A., et al. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature*, 596(7873), 583-589. [https://doi.org/10.1038/s41586-021-03819-2](https://doi.org/10.1038/s41586-021-03819-2)
    - *This paper describes the AlphaFold algorithm used to generate the high-confidence structural predictions for TMEM129 discussed in this manual.*
8.  Landrum, M. J., Lee, J. M., Benson, M., et al. (2018). ClinVar: improving access to variant interpretations and supporting evidence. *Nucleic Acids Research*, 46(D1), D1062-D1067. [https://doi.org/10.1093/nar/gkx1153](https://doi.org/10.1093/nar/gkx1153)
    - *This paper describes the ClinVar database, which is the source for the clinical variant information presented in Section 4.*
9.  Tate, J. G., Bamford, S., Jubb, H. C., et al. (2019). COSMIC: the Catalogue Of Somatic Mutations In Cancer. *Nucleic Acids Research*, 47(D1), D941-D947. [https://doi.org/10.1093/nar/gky1015](https://doi.org/10.1093/nar/gky1015)
    - *This paper describes the COSMIC database, which is the source for the somatic cancer mutations presented in Section 4.*
10. Szklarczyk